Stocks & Investing
Stocks and Investing
Stocks and Investing
Fri, January 20, 2023
[ Fri, Jan 20th 2023
] - WOPRAI
[ Fri, Jan 20th 2023
] - WOPRAI
[ Fri, Jan 20th 2023
] - WOPRAI
[ Fri, Jan 20th 2023
] - WOPRAI
[ Fri, Jan 20th 2023
] - WOPRAI
[ Fri, Jan 20th 2023
] - WOPRAI
[ Fri, Jan 20th 2023
] - WOPRAI
[ Fri, Jan 20th 2023
] - WOPRAI
[ Fri, Jan 20th 2023
] - WOPRAI
[ Fri, Jan 20th 2023
] - WOPRAI
[ Fri, Jan 20th 2023
] - WOPRAI
Thu, January 19, 2023
[ Thu, Jan 19th 2023
] - WOPRAI
[ Thu, Jan 19th 2023
] - WOPRAI
[ Thu, Jan 19th 2023
] - WOPRAI
[ Thu, Jan 19th 2023
] - WOPRAI
[ Thu, Jan 19th 2023
] - WOPRAI
[ Thu, Jan 19th 2023
] - WOPRAI
[ Thu, Jan 19th 2023
] - WOPRAI
[ Thu, Jan 19th 2023
] - WOPRAI
[ Thu, Jan 19th 2023
] - WOPRAI
[ Thu, Jan 19th 2023
] - WOPRAI
[ Thu, Jan 19th 2023
] - WOPRAI
[ Thu, Jan 19th 2023
] - WOPRAI
[ Thu, Jan 19th 2023
] - WOPRAI
[ Thu, Jan 19th 2023
] - WOPRAI
[ Thu, Jan 19th 2023
] - WOPRAI
[ Thu, Jan 19th 2023
] - WOPRAI
[ Thu, Jan 19th 2023
] - WOPRAI
Glen Santangelo Downgraded (TEVA) to Hold and Increased Target to $12 on, Jan 19th, 2023
Glen Santangelo of Jefferies, Downgraded "Teva Pharmaceutical Industries Limited" (TEVA) to Hold and Increased Target from $10 to $12 on, Jan 19th, 2023.
Glen has made no other calls on TEVA in the last 4 months.
There are 3 other peers that have a rating on TEVA. Out of the 3 peers that are also analyzing TEVA, 1 agrees with Glen's Rating of Hold. Following is the relevant analyst calls for the last 4 months
- Gary Nachman of "BMO Capital" Maintained at Hold with Decreased Target to $10 on, Monday, November 7th, 2022
These are the ratings of the 2 analyists that currently disagree with Glen
- David Amsellem of "Piper Sandler" Maintained at Sell with Decreased Target to $7 on, Wednesday, November 23rd, 2022
- Chris Schott of "JP Morgan" Downgraded from Hold to Sell and Decreased Target to $10 on, Monday, November 14th, 2022
